Eisai Co., Ltd. - LEQEMBI Intravenous Infusion Approved for the Treatment of Alzheimer's disease in Japan

TOKYO - Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta monoclonal antibody LEQEMBI Intravenous Infusion has been approved in Japan as a...

Related Keywords

Massachusetts ,United States ,Israel ,Japan ,Canada ,Cambridge ,Cambridgeshire ,United Kingdom ,Australia ,China ,Tsukuba ,Ibaraki ,South Korea ,Tokyo ,Switzerland ,Great Britain ,Japanese ,Christophera Viehbacher ,Haruo Naito ,Alzheimer Network Trials Unit ,Washington University School Of Medicine ,National Institutes Of Health ,Ministry Of Health ,Alzheimer Clinical Trial Consortium ,Exchange Commission ,Drug Administration ,Nasdaq ,Tsukuba Research Laboratories ,Biogen Inc ,Eisai Co Ltd ,United Nations Sustainable Development Goals Sdgs ,Ad Cooperative Study ,National Institute On ,Clinical Dementia Rating Sum ,Daily Living Scale ,Mild Cognitive Impairment ,Clinical Trials ,New England Journal ,Chief Executive Officer ,Research Laboratories ,Biogen Japan ,Marketing Authorization ,Access Pathway ,Clinical Trial Consortium ,Tau Nexgen ,Dominantly Inherited ,University School ,Corporate Concept ,United Nations Sustainable Development Goals ,Private Securities Litigation Reform Act ,News Publishing ,Markets ,